These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33332545)

  • 21. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter surveillance of
    Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C; Nordmann P; Poirel L
    J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
    Belley A; Morrissey I; Hawser S; Kothari N; Knechtle P
    J Glob Antimicrob Resist; 2021 Jun; 25():93-101. PubMed ID: 33746112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sigmoid
    Knechtle P; Shapiro S; Morrissey I; De Piano C; Belley A
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0092621. PubMed ID: 34097479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain.
    Hernández-García M; García-Castillo M; Nieto-Torres M; Bou G; Ocampo-Sosa A; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Oliver A; Ruiz-Garbajosa P; Cantón R
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):279-296. PubMed ID: 38041722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
    Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
    Bassetti M; Giacobbe DR; Robba C; Pelosi P; Vena A
    Curr Opin Infect Dis; 2020 Dec; 33(6):474-481. PubMed ID: 33060469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model.
    Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2023 Mar; 78(3):692-702. PubMed ID: 36640133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1
    Piccirilli A; Segatore B; Brisdelli F; Amicosante G; Perilli M
    Int J Antimicrob Agents; 2021 Jan; 57(1):106228. PubMed ID: 33246038
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Lasko MJ; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.